eGFR, glycemic control, and BMI are modifiable risk factors for DKD, such that the rational use of sodium/glucose cotransporter-2 inhibitors (SGLT2i) and other drugs in patients with T2DM may be beneficial. The gene discussed is SLC5A2; the disease is diabetic kidney disease.